The medical network July 28 clinical feedback 204 medicine shortage, anhui the pharmaceutical enterprise, the demand to disclose the factory price. 

 

▍ anhui 204 drugs ex-factory price that must be disclosed 

 

On July 27, anhui pharmaceutical collection platform issued a notice concerning the verification and verification of the supply and production inventory of pharmaceutical products. The production and distribution of some medicines can be found. 

 

Among them, about 204 drugs for pharmaceutical production enterprise of anhui province to fill out: currently in production in enterprise production list address, drug varieties, as well as those in drug sales in 2016, the factory price, production enterprise has API approval number and whether in the past two years in production. 

 

List since 2016 the production of drugs (including production quantity, production batch, and production time etc.), the finished goods inventory (according to completion the inventory of the day), the second half of 2017, a preliminary production scheduling plan, API source and supply is stable, and so on and so forth. (please refer to the attachment for the product catalog) 

 

▍ drug shortages, countries have the means to 

 

These drugs are a shortage of clinical response, and the name of the notice is confirmed. The original intention of anhui for these products may be to solve the problem once and for all. The same is true of big policy. 

 

On June 28, state development planning commission, the national development and reform commission, the ministry, the ministry of finance, people club department, ministry of commerce, state-owned assets supervision and administration commission of the state council, state administration for industry and commerce, the national food administration of drug safety and other nine departments jointly issued on the reform to perfect the shortage of drug supply security mechanism of the implementation opinions "(countries who medicine ZhengFa [2017] no. 37) (hereinafter referred to as" implementation opinion "), announced that nine departments joint management shortage of medicine in a series of measures. 

 

"Opinion" is clear: shortage of medicine implementation point production. Comprehensive clinical required, small dosage or market price is low and the shortage of power enterprise production factors, selecting the fixed-point production varieties, through the government pricing, price negotiations, market set a variety of ways, such as to determine the unified purchase price, reasonable supply security area, bidding to determine fixed-point production enterprise, the net purchase directly. 

 

▍ ground floor price, the government is likely to underwriting 

 

The national health and family planning commission (NHFPC) also mentioned in the second day of the interpretation of the implementation opinion that the company was not worried about profits and development. 

 

In combination with the policy, anhui requires local pharmaceutical companies to publish the prices of 204 shortages of medicines, which may mean that there is an underwriting. In this way, the shortage of medicines is expected to be alleviated. 

 

In addition, anhui pharmaceutical collection platform requires the product information provided by the enterprise, and the relevant information should be reported to anhui provincial drug collection center before work on August 3 (Thursday). 

 

The attached: